All state drug regulators should be merged with CDSCO for the quality of drugs, Dr. Krishna Ella's suggestion
Dr. Krishna Ella, Founder, Bharat Biotech, said that the entire Indian pharmaceutical industry cannot be maligned because of a few cases.
Time to Read 2 Min
To ensure 'one quality one standard' for Indian drugs, Dr Krishna Ella, founder of vaccine maker Bharat Biotech, has suggested that all state drug regulators align with the Central Drugs Standard Control Organization (CDSCO). should be merged with.
His statement has come in the backdrop of questions being raised about the quality of Indian medicines in the past. Let me tell you, recently Tamil Nadu based Global Pharma Healthcare had to withdraw all eye drops after the cases of eye infection were reported in the US. Last year, cases of children's deaths were reported in Gambia and Uzbekistan allegedly from cough syrup manufactured in India.
In the context of these matters, he said that the entire Indian pharmaceutical industry cannot be maligned because of a few matters. He said that even in western countries some companies have been penalized for quality issues. Ella said that there should be a regulator for drugs in India. All the state drug regulatory bodies should be merged into the Central Drugs Standard Control Organization (CDSCO) and this would solve the problem. He said that political decision and commitment is needed for this.
supply of nasal covid vaccine started
Bharat Biotech has started supplying its Nasal Covid vaccine. The company's executive chairman Dr. Krishna Ella said on Sunday that we have sent three lakh doses of Nasal Kovid vaccine to some hospitals two days ago. He made this statement on the sidelines of a program in Bengaluru. A bilateral agreement was signed between the University of Wisconsin (UW)-Madison Global Health Institute (GHI) and Ella Foundation on Sunday to establish the UW-Madison One Health Center in Bengaluru.
The world's first nasal covid vaccine iNCOVACC was launched on 26 January. It is now available on the Covin platform. Its cost is Rs 800 for private markets and Rs 325 for governments.
On the question of the media regarding the export of Bharat Biotech's vaccine, Dr. Ella said that some countries and international agencies have approached the company for the nasal vaccine. Ella said that the UW-Madison One Health Center in Bengaluru is expected to be operational by the end of 2023. He said that this health center will help in the development and production of new vaccines for India. In addition, it will provide Indian students and researchers access to UW expertise and training, and build research capacity in India.